GlycoMimetics Inc expected to post a loss of 15 cents a share - Earnings Preview

Crescent Biopharma

25/03/2024 12:33

* GlycoMimetics Inc  GLYC.OQ   GLYC.O  is expected to show
no
change in quarterly revenue when it reports  results on March 27
for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for GlycoMimetics Inc is for
a
loss of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $8.00​, above​ its last closing price of $2.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.14       -0.14      -0.14     Met     2.3
 Jun. 30 2023  -0.18       -0.18      -0.13     Beat    29.1
 Mar. 31 2023  -0.16       -0.17      -0.17     Met     -2​
 Dec. 31 2022  -0.17       -0.17      -0.19     Missed  -14
 ​​Sep.        -0.23       -0.26      -0.16     Beat    39.2
 30 2022                                                
 Jun. 30 2022  -0.29       -0.28      -0.25     Beat    12.3​
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    8.7
 Dec. 31 2021  -0.39       -0.34      -0.33     Beat    2.2
 This summary was machine generated March 25 at 12:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)